About this episode

Diane Simeone, MD discusses the breakthrough of daraxonrasib in improving survival rates for patients with metastatic pancreatic cancer.

In a conversation with CancerNetwork®, Diane Simeone, MD, discussed the implications of daraxonrasib demonstrating meaningful improvements in survival among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in the phase 3 RASolute 302 trial (NCT06625320). Topline findings from the trial showed that the novel multiselective RAS(ON) inhibitor approximately doubled the median overall survival (OS) compared with investigator’s choice of chemotherapy, with survival benefits extending to those with different RAS mutations and RAS wild-type disease. Simeone spoke about the significance of these results in the context of the pancreatic cancer field, breaking down how daraxonrasib’s mechanism of action as a pan-RAS inhibitor may open a “new fronter” beyond standard-of-care chemotherapy and platinum-based regimens. She also touched upon the prominent toxicities that have emerged with daraxonrasib, including rashes, while emphasizing the balancing of risk and benefit as part of further optimizing RAS therapeutics. The discussion also highlighted strategies for expanding genetic testing for patients with pancreatic cancer, as Simeone described the importance of receiving…

People in this episode

Host: CancerNetwork

Guests: Diane Simeone, MD, Diane Simeone

Topics covered

• metastatic pancreatic cancer
• daraxonrasib
• RAS mutations
• survival improvements
• personalized treatment
• genetic testing

Keywords

• daraxonrasib
• metastatic pancreatic cancer
• survival
• RAS mutations
• chemotherapy
• genetic testing
• personalized treatment

Mentioned in this episode

Organizations: CancerNetwork

Products: daraxonrasib

Books & works: Pancreatic Cancer Early Detection (PRECEDE) Consortium

Explore listener stats, chart rankings, contacts and more on the Oncology On The Go podcast page.